Abraxane for Metastatic Pancreatic Cancer - Details


( Dernière mise à jour : octobre 8, 2014)
Generic Name:
Nab paclitaxel
État du projet:
Terminé
Domaine thérapeutique:
Metastatic Pancreatic Cancer
Fabricant:
Celgene Inc.
Brand Name:
Abraxane
Gamme de produits:
Examen en vue du remboursement
Numéro de projet :
PC0037-000

Détails


Strength:
100 mg/vial
Tumour Type:
Gastrointestinal
Indications:
Metastatic Pancreatic Cancer
Funding Request:
For the first line treatment of patients with metastatic adenocarcinoma of the pancreas, in combination with gemcitabine.
Review Status:
Complete
Pre Noc Submission:
Yes
Sponsor:
Celgene Inc.
Submission Date:
Submission Deemed Complete:
Priorisation demandée:
Non demandée
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommandation:
Remboursement sous critères cliniques ou conditions
Funding Request:
For the first line treatment of patients with metastatic adenocarcinoma of the pancreas, in combination with gemcitabine.
pERC Meeting:
Final Recommendation Issued:

Fichiers

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.